| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/22/2009 | US20090022663 Antibodies and related molecules that bind to 161p2f10b proteins |
| 01/22/2009 | US20090022662 Cancerous disease modifying antibodies |
| 01/22/2009 | US20090022661 Cancerous disease modifying antibodies |
| 01/22/2009 | US20090022660 Monoclonal antibodies comprising cytotoxic agent capable of inducing antibody dependent cellular cytotoxicity directed towards tumorus tissues |
| 01/22/2009 | US20090022659 Antibodies to TNF alpha and use thereof |
| 01/22/2009 | US20090022658 Modified antibodies and methods of use |
| 01/22/2009 | US20090022657 Novel CXCL8 antagonists |
| 01/22/2009 | US20090022656 Lipidated glycoprotein particles and methods of use |
| 01/22/2009 | US20090022655 boron neutron capture therapy, attaching antibody (IgG) cell-targeting species to BN nanostructures to form composite, administering to target tumors, activating boron in composite; indirect source of radiation therapy, delivery vehicles for radio- and chemo-therapeutic materials, imaging agents |
| 01/22/2009 | CA2729011A1 Varicella zoster virus-virus like particles (vlps) and antigens |
| 01/22/2009 | CA2696437A1 Production and use of epitope-tagged hepatitis c virus particle |
| 01/22/2009 | CA2694011A1 Survivin peptides as cancer vaccines |
| 01/22/2009 | CA2693956A1 Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant |
| 01/22/2009 | CA2693936A1 Conjugate purification |
| 01/22/2009 | CA2693899A1 Chimeric varicella zoster virus-virus like particles |
| 01/22/2009 | CA2693863A1 Engineered anti-alpha v- integrin hybrid antibodies |
| 01/22/2009 | CA2693771A1 Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor |
| 01/22/2009 | CA2693255A1 Anti-cd79b antibodies and immunoconjugates and methods of use |
| 01/22/2009 | CA2693137A1 Engineered scfv against bovine herpes virus type i |
| 01/22/2009 | CA2692912A1 An anti-cancer cytotoxic monoclonal antibody |
| 01/22/2009 | CA2692826A1 An anti-cancer cytotoxic monoclonal antibody |
| 01/22/2009 | CA2692823A1 An anti-cancer cytotoxic monoclonal antibody |
| 01/22/2009 | CA2692819A1 Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| 01/22/2009 | CA2692693A1 Optimized dna and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins |
| 01/22/2009 | CA2691847A1 Treatments and diagnostics for cancer, inflammatory disorders and autoimmune disorders |
| 01/22/2009 | CA2691406A1 Preprocalcitonin antigen t epitopes |
| 01/22/2009 | CA2685495A1 Mutated e. coli heat-labile enterotoxin |
| 01/21/2009 | EP2017617A1 Wound dressing |
| 01/21/2009 | EP2017355A1 Gene associated with arteriosclerotic disease, and use thereof |
| 01/21/2009 | EP2017343A2 Protein A based binding domains with desirable activities |
| 01/21/2009 | EP2017342A1 Recombinant allergen with reduced enzymatic activity |
| 01/21/2009 | EP2017333A1 Feline cell capable of being cultured without animal protein, and method for production of virus and method for production of vaccine using the feline cell |
| 01/21/2009 | EP2016954A1 Antibodies against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and metabolites thereof |
| 01/21/2009 | EP2016953A2 Vascular endothelial cell growth factor antagonists and uses thereof |
| 01/21/2009 | EP2016952A2 A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| 01/21/2009 | EP2016948A2 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| 01/21/2009 | EP2016930A2 A cell therapy method for the treatment of tumors |
| 01/21/2009 | EP2016419A2 Methods for the in vitro screening of compounds inhibiting production of infectious hiv-1 virions |
| 01/21/2009 | EP2016172A1 Diagnostic methods for determining treatment |
| 01/21/2009 | EP2016162A2 Humanized monoclonal antibodies to hepatocyte growth factor |
| 01/21/2009 | EP2016090A2 Genetic adjuvants for viral vaccines |
| 01/21/2009 | EP2015776A1 Glp-1 compound/glucagon antibody compositions |
| 01/21/2009 | EP2015775A1 Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody |
| 01/21/2009 | EP2015774A1 Influenza virus vaccine |
| 01/21/2009 | EP2015773A2 Assessment of the effects of topical administration of chemodenervating pharmaceuticals |
| 01/21/2009 | EP2015772A2 Agent for the treatment of malignant diseases |
| 01/21/2009 | EP2015771A1 Modulation of t helper cell-mediated immune responses |
| 01/21/2009 | EP2015768A1 Methods for treating kidney disorders |
| 01/21/2009 | EP1793853B1 Liquid allergy vaccine formulation for oromucosal administration |
| 01/21/2009 | EP1585770B1 Recognition molecules for the treatment and detection of tumours |
| 01/21/2009 | EP1569680B1 Treatment of diabetes |
| 01/21/2009 | EP1567175B1 Sterile immunogenic non-tumorigenic tumor cell compositions and methods |
| 01/21/2009 | EP1487273B1 Compositions and methods for treatment of microbial infections |
| 01/21/2009 | EP1432443B1 Angiotensin peptide-carrier conjugates and uses thereof |
| 01/21/2009 | EP1399563B1 Moraxella (branhamella) catarrhalis antigens |
| 01/21/2009 | EP1353691B1 Molecular antigen array presenting amyloid beta |
| 01/21/2009 | EP1335973B1 human adenylate cyclase |
| 01/21/2009 | EP1261701B1 FULL-LENGTH INFECTIOUS cDNA CLONES OF TICK BORNE FLAVIVIRUS |
| 01/21/2009 | EP1105495B2 Method for producing yeast expressed hpv types 6 and 16 capsid proteins |
| 01/21/2009 | EP1053021B1 Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media |
| 01/21/2009 | EP1019438B1 Apoptosis-related compounds and their use |
| 01/21/2009 | EP1007546B1 Molecular mimetics of meningococcal b epitopes |
| 01/21/2009 | EP0912195B1 Vaccine comprising antigens bound to carriers through labile bonds |
| 01/21/2009 | CN101351478A Uses of anti-CD40 antibodies |
| 01/21/2009 | CN101351477A Anti-CD19 antibodies with reduced immunogenicity |
| 01/21/2009 | CN101351476A Antibodies with glycosylated in the variable region |
| 01/21/2009 | CN101351228A Immune stimulation speciality of compound containing modified immune irritation dinucleotide base on oligonucleotide |
| 01/21/2009 | CN101351226A Cytotoxic antibodies targeting antibodies inhibiting factor VIII |
| 01/21/2009 | CN101351225A Tumor-targeted nanodelivery systems to improve early mri detection of cancer |
| 01/21/2009 | CN101351224A Hypoallergenic variants of the major allergen from Betula verrucosa pollen |
| 01/21/2009 | CN101351223A Multiclade HIV vaccines |
| 01/21/2009 | CN101351222A Mannose immunogens for HIV-1 |
| 01/21/2009 | CN101351221A Outer coat protein PA5158 of pseudomonas aeruginosa |
| 01/21/2009 | CN101348526A Anti-interleukin-8 antibody |
| 01/21/2009 | CN101348525A Anti-schistosomiasis monoclonal antibody NP11-4 single-chain antibody, preparation and use thereof |
| 01/21/2009 | CN101348521A Aminoacid mimic epitope of human B lymphocyte stimulating factor receptor and use thereof |
| 01/21/2009 | CN101348467A Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 01/21/2009 | CN101347617A Refined polyvalent anti-snake poison lyophilized blood serum and using method |
| 01/21/2009 | CN101347616A Composing prescription of novel safe JY immunoadjuvant system and uses thereof |
| 01/21/2009 | CN101347457A Indirect type immunological tolerance revulsion |
| 01/21/2009 | CN100453647C DNA vaccine carrier of carring SV40 enhancer element |
| 01/21/2009 | CN100453645C Antibodies against insulin-like growth factor i receptor and uses thereof |
| 01/21/2009 | CN100453556C Multispecific deimmunized CD3-binders |
| 01/20/2009 | US7479553 Nucleic acids encoding mutant disulfide bond-stabilized human immunodeficiency virus type 1 (HIV-1) gp140 envelope glycoproteins |
| 01/20/2009 | US7479550 For Alzheimer's Disease; Th2 type immunostimulation directed to A beta |
| 01/20/2009 | US7479547 Using shuffled viral protein sequences as tool in generating antibodies for diagnosis, prevention and treatment of viral disease |
| 01/20/2009 | US7479544 biological conjugated drug binding with a detectable label, or toxin maytansine and calicheamicin; monoclonal antibody as antiinflammatory agents in the therapeutic treatment and diagnostic detection of immune disorders in mammals; biodrugs |
| 01/20/2009 | US7479543 chimeric antibodies comprising variable domain peptides, DNA codes for the antibodies, expression vectors, host cells and a process of culturing the host cells to produce the monoclonal antibodies, used for immunotherapy; nonimmunogenic |
| 01/20/2009 | US7479542 polymer conjugated drug contains polyethylene glycol covalently attached to the polypeptide; biodrug for treating hepatitis C; new kind of interleukins; fusion proteins |
| 01/20/2009 | US7479539 Hedgehog fusion proteins |
| 01/20/2009 | US7479482 For treatment of neurodegenerative disorders |
| 01/20/2009 | US7479386 Hepatitis X virus for use in generation of antibody and vaccine compositions for use in diagnosis, prevention and treatment viral infection; immunotherapeutic and diagnostics |
| 01/20/2009 | US7479376 Using caudal-1 gene (CDX-1) as diagnostic indicator of stomach or esophageal cancer; immunodiagnostics |
| 01/20/2009 | US7479367 In vivo assay and molecular markers for testing the phenotypic stability of cell populations and selected cell populations for autologous transplantation |
| 01/20/2009 | US7479285 Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
| 01/20/2009 | US7479284 Babesia canis vaccine |
| 01/20/2009 | US7479283 Synergistic; LPF, a sub-unit protein vaccine based on pertussis toxin, is not required |
| 01/20/2009 | US7479282 Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof |
| 01/20/2009 | US7479281 Locally administering botulinum toxin powder to a patient using a using a needleless syringe connected to a tank of compressed inert gas, such as helium, for producing a supersonic gas flow; gold, platinum, tungsten or ice crystal carrier; pain is alleviated within 1 to 7 days of administration |
| 01/20/2009 | US7479280 Papilloma virus capsid support comprising chimeric lymphocyte epitope for use in identifying modulators to treat and prevention cell proiferative, autoimmune and viral diseases |